| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Echocardiography | 34 | 2021 | 933 | 5.550 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 15 | 2012 | 94 | 3.080 |
Why?
|
| Echocardiography, Transesophageal | 14 | 2020 | 346 | 2.920 |
Why?
|
| Guideline Adherence | 12 | 2020 | 226 | 2.820 |
Why?
|
| Cardiology | 10 | 2021 | 113 | 2.680 |
Why?
|
| Practice Guidelines as Topic | 14 | 2016 | 1034 | 1.930 |
Why?
|
| Cardiovascular Diseases | 12 | 2022 | 703 | 1.810 |
Why?
|
| Image Enhancement | 10 | 2012 | 566 | 1.780 |
Why?
|
| Heart Diseases | 8 | 2018 | 297 | 1.690 |
Why?
|
| Exercise Test | 10 | 2021 | 164 | 1.670 |
Why?
|
| Image Interpretation, Computer-Assisted | 7 | 2014 | 681 | 1.470 |
Why?
|
| American Heart Association | 6 | 2020 | 86 | 1.420 |
Why?
|
| Ventricular Dysfunction, Left | 10 | 2007 | 327 | 1.340 |
Why?
|
| Inpatients | 2 | 2021 | 308 | 1.230 |
Why?
|
| Algorithms | 8 | 2014 | 1857 | 1.170 |
Why?
|
| Societies, Medical | 9 | 2016 | 561 | 1.130 |
Why?
|
| Cardiac Imaging Techniques | 4 | 2016 | 25 | 1.130 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2019 | 3429 | 1.120 |
Why?
|
| Peripheral Vascular Diseases | 4 | 2009 | 61 | 1.120 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2018 | 126 | 1.110 |
Why?
|
| Coronary Artery Disease | 8 | 2012 | 358 | 1.010 |
Why?
|
| Electrocardiography | 5 | 2018 | 495 | 0.990 |
Why?
|
| Syncope | 2 | 2021 | 34 | 0.980 |
Why?
|
| Heart | 5 | 2009 | 572 | 0.960 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2021 | 597 | 0.960 |
Why?
|
| Humans | 107 | 2022 | 88365 | 0.940 |
Why?
|
| Myocardial Perfusion Imaging | 5 | 2012 | 47 | 0.900 |
Why?
|
| Erectile Dysfunction | 3 | 2009 | 75 | 0.860 |
Why?
|
| Myocardial Ischemia | 5 | 2008 | 161 | 0.830 |
Why?
|
| Osteoarthritis, Knee | 7 | 2019 | 65 | 0.830 |
Why?
|
| Pattern Recognition, Automated | 4 | 2014 | 218 | 0.800 |
Why?
|
| Echocardiography, Stress | 2 | 2012 | 20 | 0.790 |
Why?
|
| Magnetic Resonance Imaging, Cine | 5 | 2020 | 161 | 0.780 |
Why?
|
| Brain | 4 | 2012 | 2257 | 0.760 |
Why?
|
| Heart Murmurs | 1 | 2020 | 6 | 0.730 |
Why?
|
| Electronic Health Records | 2 | 2021 | 340 | 0.730 |
Why?
|
| Protein Multimerization | 4 | 2016 | 173 | 0.720 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 53 | 0.710 |
Why?
|
| Advisory Committees | 3 | 2015 | 88 | 0.680 |
Why?
|
| Diazomethane | 1 | 2018 | 5 | 0.660 |
Why?
|
| Sensitivity and Specificity | 15 | 2012 | 2019 | 0.630 |
Why?
|
| Unnecessary Procedures | 3 | 2021 | 51 | 0.630 |
Why?
|
| Coronary Disease | 2 | 2010 | 261 | 0.630 |
Why?
|
| Aged | 35 | 2021 | 18878 | 0.630 |
Why?
|
| Quality of Health Care | 2 | 2014 | 383 | 0.620 |
Why?
|
| Cardiomyopathies | 4 | 2020 | 260 | 0.600 |
Why?
|
| Pandemics | 2 | 2021 | 760 | 0.590 |
Why?
|
| Betacoronavirus | 1 | 2020 | 260 | 0.570 |
Why?
|
| Medicare | 1 | 2020 | 420 | 0.560 |
Why?
|
| Academic Medical Centers | 2 | 2009 | 383 | 0.560 |
Why?
|
| Ischemic Attack, Transient | 3 | 2008 | 182 | 0.560 |
Why?
|
| Preoperative Care | 3 | 2021 | 399 | 0.550 |
Why?
|
| Reproducibility of Results | 15 | 2014 | 2743 | 0.540 |
Why?
|
| Middle Aged | 41 | 2021 | 25612 | 0.540 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 1 | 2015 | 2 | 0.520 |
Why?
|
| Myocardium | 3 | 2009 | 570 | 0.510 |
Why?
|
| United States | 23 | 2021 | 6867 | 0.510 |
Why?
|
| Heart Ventricles | 4 | 2019 | 778 | 0.500 |
Why?
|
| Thoracic Surgery | 2 | 2012 | 43 | 0.500 |
Why?
|
| Prevalence | 7 | 2020 | 1246 | 0.500 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 318 | 0.500 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 303 | 0.500 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 96 | 0.480 |
Why?
|
| Fluorescence Resonance Energy Transfer | 3 | 2015 | 95 | 0.480 |
Why?
|
| Male | 43 | 2021 | 41896 | 0.470 |
Why?
|
| Knee Injuries | 4 | 2015 | 54 | 0.470 |
Why?
|
| Nuclear Medicine | 3 | 2008 | 12 | 0.460 |
Why?
|
| Coronary Circulation | 4 | 2007 | 131 | 0.460 |
Why?
|
| Knee Joint | 5 | 2015 | 166 | 0.460 |
Why?
|
| Cardiac Catheterization | 2 | 2012 | 298 | 0.460 |
Why?
|
| Predictive Value of Tests | 9 | 2021 | 1704 | 0.450 |
Why?
|
| Stroke | 3 | 2008 | 976 | 0.440 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2003 | 42 | 0.420 |
Why?
|
| Health Services Misuse | 1 | 2012 | 19 | 0.420 |
Why?
|
| Health Policy | 1 | 2014 | 185 | 0.410 |
Why?
|
| Female | 42 | 2021 | 45621 | 0.390 |
Why?
|
| Internship and Residency | 1 | 2021 | 1036 | 0.390 |
Why?
|
| Blood Pressure | 3 | 2010 | 891 | 0.370 |
Why?
|
| Exercise | 2 | 2019 | 321 | 0.370 |
Why?
|
| Radiopharmaceuticals | 4 | 2020 | 192 | 0.360 |
Why?
|
| Prospective Studies | 9 | 2021 | 4263 | 0.350 |
Why?
|
| Risk Assessment | 10 | 2021 | 2285 | 0.350 |
Why?
|
| Risk Factors | 15 | 2019 | 5435 | 0.350 |
Why?
|
| Diagnostic Imaging | 4 | 2016 | 476 | 0.350 |
Why?
|
| Heart Rate | 2 | 2010 | 492 | 0.350 |
Why?
|
| Utilization Review | 3 | 2020 | 23 | 0.350 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2011 | 113 | 0.340 |
Why?
|
| Ventricular Function, Right | 1 | 2010 | 145 | 0.340 |
Why?
|
| Ankle | 1 | 2009 | 20 | 0.340 |
Why?
|
| Brachial Artery | 1 | 2009 | 36 | 0.340 |
Why?
|
| Logistic Models | 8 | 2014 | 1204 | 0.330 |
Why?
|
| Blood Pressure Determination | 1 | 2009 | 60 | 0.330 |
Why?
|
| Coronary Angiography | 2 | 2012 | 238 | 0.330 |
Why?
|
| HEK293 Cells | 5 | 2018 | 635 | 0.320 |
Why?
|
| Internet | 1 | 2011 | 317 | 0.320 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2007 | 104 | 0.320 |
Why?
|
| Embolism | 1 | 2008 | 32 | 0.320 |
Why?
|
| Community Health Centers | 1 | 2009 | 115 | 0.310 |
Why?
|
| Patient Selection | 2 | 2010 | 689 | 0.310 |
Why?
|
| Ambulatory Care | 1 | 2009 | 186 | 0.310 |
Why?
|
| Organotechnetium Compounds | 2 | 2007 | 11 | 0.310 |
Why?
|
| Heart Atria | 2 | 2007 | 281 | 0.310 |
Why?
|
| Pulmonary Embolism | 2 | 2008 | 228 | 0.300 |
Why?
|
| Menisci, Tibial | 2 | 2019 | 25 | 0.300 |
Why?
|
| Organophosphorus Compounds | 2 | 2007 | 55 | 0.300 |
Why?
|
| Carotid Arteries | 1 | 2008 | 127 | 0.300 |
Why?
|
| Documentation | 2 | 2021 | 103 | 0.300 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1142 | 0.290 |
Why?
|
| Bone Marrow | 3 | 2013 | 442 | 0.290 |
Why?
|
| Thrombosis | 2 | 2007 | 301 | 0.290 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2006 | 8 | 0.280 |
Why?
|
| Endocardium | 2 | 2004 | 98 | 0.280 |
Why?
|
| Myocardial Stunning | 1 | 2006 | 12 | 0.280 |
Why?
|
| Contrast Media | 5 | 2008 | 1084 | 0.280 |
Why?
|
| Multivariate Analysis | 5 | 2007 | 994 | 0.280 |
Why?
|
| Hospitalization | 1 | 2012 | 869 | 0.280 |
Why?
|
| Arterio-Arterial Fistula | 1 | 2006 | 6 | 0.270 |
Why?
|
| Myocardial Infarction | 3 | 2021 | 372 | 0.270 |
Why?
|
| Adult | 19 | 2021 | 26266 | 0.260 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2006 | 41 | 0.260 |
Why?
|
| Hypertension | 2 | 2010 | 730 | 0.260 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2012 | 1226 | 0.250 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2011 | 191 | 0.250 |
Why?
|
| Retrospective Studies | 11 | 2021 | 8852 | 0.240 |
Why?
|
| Prognosis | 7 | 2019 | 3746 | 0.240 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 112 | 0.240 |
Why?
|
| Severity of Illness Index | 5 | 2014 | 1841 | 0.240 |
Why?
|
| Mass Screening | 1 | 2009 | 631 | 0.240 |
Why?
|
| Cartilage, Articular | 2 | 2015 | 68 | 0.240 |
Why?
|
| Anemia, Hemolytic | 2 | 2004 | 19 | 0.240 |
Why?
|
| Vascular Surgical Procedures | 1 | 2005 | 148 | 0.240 |
Why?
|
| Ventricular Function, Left | 3 | 2021 | 602 | 0.240 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2004 | 16 | 0.240 |
Why?
|
| Education, Medical, Graduate | 2 | 2021 | 384 | 0.240 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2004 | 8 | 0.240 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 6704 | 0.240 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2004 | 27 | 0.230 |
Why?
|
| Aortic Diseases | 1 | 2004 | 99 | 0.230 |
Why?
|
| Thallium | 1 | 2003 | 8 | 0.230 |
Why?
|
| Pulmonary Artery | 1 | 2006 | 312 | 0.230 |
Why?
|
| Brain Ischemia | 1 | 2008 | 402 | 0.230 |
Why?
|
| Ischemia | 1 | 2005 | 251 | 0.230 |
Why?
|
| Aortic Valve Stenosis | 1 | 2005 | 143 | 0.230 |
Why?
|
| Point-of-Care Systems | 2 | 2020 | 144 | 0.230 |
Why?
|
| Pheochromocytoma | 1 | 2004 | 50 | 0.230 |
Why?
|
| Time Factors | 8 | 2019 | 5302 | 0.220 |
Why?
|
| Schools, Nursing | 1 | 2002 | 1 | 0.220 |
Why?
|
| Perioperative Nursing | 1 | 2002 | 2 | 0.220 |
Why?
|
| Radionuclide Imaging | 2 | 2016 | 221 | 0.220 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2004 | 82 | 0.220 |
Why?
|
| Clinical Competence | 3 | 2021 | 779 | 0.220 |
Why?
|
| Surveys and Questionnaires | 5 | 2019 | 2586 | 0.220 |
Why?
|
| Heart Neoplasms | 2 | 2019 | 63 | 0.220 |
Why?
|
| Inservice Training | 1 | 2002 | 38 | 0.220 |
Why?
|
| Angina Pectoris | 1 | 2002 | 28 | 0.210 |
Why?
|
| Primary Health Care | 3 | 2022 | 350 | 0.210 |
Why?
|
| Cardiovascular System | 1 | 2022 | 62 | 0.210 |
Why?
|
| Mitral Valve | 2 | 2004 | 258 | 0.210 |
Why?
|
| Coronary Vessels | 1 | 2003 | 190 | 0.200 |
Why?
|
| Age Distribution | 3 | 2010 | 200 | 0.200 |
Why?
|
| Laboratories | 1 | 2021 | 44 | 0.200 |
Why?
|
| Hospitals | 2 | 2021 | 298 | 0.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 379 | 0.200 |
Why?
|
| Radiology | 2 | 2016 | 197 | 0.200 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2001 | 17 | 0.190 |
Why?
|
| Abdomen | 1 | 2021 | 121 | 0.190 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2001 | 38 | 0.190 |
Why?
|
| Receptors, Cell Surface | 2 | 2013 | 289 | 0.190 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2001 | 90 | 0.190 |
Why?
|
| Family Practice | 1 | 2001 | 85 | 0.180 |
Why?
|
| Physical Examination | 2 | 2020 | 148 | 0.180 |
Why?
|
| Sarcoidosis | 1 | 2020 | 72 | 0.180 |
Why?
|
| Data Collection | 3 | 2011 | 374 | 0.180 |
Why?
|
| Periodicals as Topic | 2 | 2012 | 168 | 0.180 |
Why?
|
| Mobile Applications | 1 | 2021 | 66 | 0.170 |
Why?
|
| Disease Progression | 4 | 2019 | 1488 | 0.170 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 142 | 0.170 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 120 | 0.170 |
Why?
|
| Synovitis | 1 | 2019 | 14 | 0.170 |
Why?
|
| Posterior Cruciate Ligament | 1 | 2019 | 12 | 0.170 |
Why?
|
| Accelerometry | 1 | 2019 | 38 | 0.170 |
Why?
|
| Data Interpretation, Statistical | 2 | 2011 | 299 | 0.170 |
Why?
|
| Hip Joint | 1 | 2019 | 54 | 0.170 |
Why?
|
| Atropine | 2 | 2016 | 60 | 0.170 |
Why?
|
| Angiography | 2 | 2012 | 208 | 0.170 |
Why?
|
| Postoperative Complications | 4 | 2021 | 2276 | 0.170 |
Why?
|
| Radiation Protection | 2 | 2016 | 27 | 0.170 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2021 | 101 | 0.170 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 2 | 2009 | 12 | 0.170 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 111 | 0.170 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2018 | 14 | 0.170 |
Why?
|
| Hospitals, University | 2 | 2010 | 195 | 0.170 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2021 | 115 | 0.160 |
Why?
|
| Walking | 1 | 2019 | 89 | 0.160 |
Why?
|
| Muscarinic Antagonists | 2 | 2016 | 58 | 0.160 |
Why?
|
| Anterior Cruciate Ligament | 1 | 2019 | 50 | 0.160 |
Why?
|
| Substance P | 1 | 2018 | 61 | 0.160 |
Why?
|
| Biomarkers | 2 | 2021 | 1754 | 0.160 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 335 | 0.160 |
Why?
|
| Databases, Factual | 5 | 2021 | 846 | 0.160 |
Why?
|
| Chromatography, Liquid | 1 | 2018 | 105 | 0.160 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 104 | 0.160 |
Why?
|
| Cell Membrane | 2 | 2018 | 667 | 0.160 |
Why?
|
| Age Factors | 4 | 2015 | 1857 | 0.160 |
Why?
|
| Curriculum | 1 | 2002 | 565 | 0.150 |
Why?
|
| Receptor, Muscarinic M3 | 2 | 2015 | 12 | 0.150 |
Why?
|
| Incidence | 4 | 2016 | 1588 | 0.150 |
Why?
|
| Ligands | 1 | 2018 | 438 | 0.150 |
Why?
|
| Stroke Volume | 3 | 2021 | 460 | 0.150 |
Why?
|
| Perfusion | 2 | 2009 | 227 | 0.150 |
Why?
|
| Communication | 1 | 2021 | 452 | 0.150 |
Why?
|
| Heart Failure | 2 | 2011 | 1170 | 0.150 |
Why?
|
| Value-Based Purchasing | 1 | 2016 | 5 | 0.140 |
Why?
|
| Illinois | 3 | 2008 | 465 | 0.140 |
Why?
|
| Regional Health Planning | 1 | 2016 | 13 | 0.140 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 2016 | 2 | 0.140 |
Why?
|
| Pirenzepine | 1 | 2016 | 8 | 0.140 |
Why?
|
| Trastuzumab | 1 | 2016 | 69 | 0.130 |
Why?
|
| Musculoskeletal Diseases | 1 | 2016 | 34 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2016 | 2633 | 0.130 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2015 | 7 | 0.130 |
Why?
|
| Tibial Meniscus Injuries | 1 | 2015 | 19 | 0.130 |
Why?
|
| Endoscopy | 1 | 2019 | 339 | 0.130 |
Why?
|
| Protein Structure, Quaternary | 1 | 2015 | 99 | 0.130 |
Why?
|
| Protein Transport | 2 | 2015 | 419 | 0.130 |
Why?
|
| Aftercare | 1 | 2016 | 87 | 0.120 |
Why?
|
| Sex Factors | 2 | 2010 | 1061 | 0.120 |
Why?
|
| Diagnosis, Differential | 4 | 2008 | 1587 | 0.120 |
Why?
|
| Chicago | 2 | 2009 | 1407 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2021 | 2833 | 0.120 |
Why?
|
| Green Fluorescent Proteins | 1 | 2015 | 307 | 0.120 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2014 | 105 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 160 | 0.110 |
Why?
|
| Cyclopropanes | 1 | 2013 | 25 | 0.110 |
Why?
|
| Robotic Surgical Procedures | 1 | 2019 | 289 | 0.110 |
Why?
|
| Molecular Probe Techniques | 1 | 2013 | 9 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 565 | 0.110 |
Why?
|
| Biotinylation | 1 | 2013 | 42 | 0.110 |
Why?
|
| Butyrates | 1 | 2013 | 46 | 0.110 |
Why?
|
| Arthralgia | 1 | 2013 | 37 | 0.110 |
Why?
|
| Thiazoles | 1 | 2013 | 128 | 0.110 |
Why?
|
| Receptors, Neuropeptide | 1 | 2012 | 7 | 0.100 |
Why?
|
| Microspheres | 2 | 2002 | 108 | 0.100 |
Why?
|
| Calibration | 1 | 2012 | 102 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2016 | 375 | 0.100 |
Why?
|
| Acute Disease | 3 | 2015 | 838 | 0.100 |
Why?
|
| Neuropeptides | 1 | 2012 | 113 | 0.100 |
Why?
|
| Bone Density | 1 | 2013 | 209 | 0.100 |
Why?
|
| Models, Cardiovascular | 1 | 2012 | 104 | 0.100 |
Why?
|
| Acetamides | 1 | 2011 | 26 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 427 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 3655 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 197 | 0.100 |
Why?
|
| Evidence-Based Practice | 1 | 2011 | 45 | 0.100 |
Why?
|
| Diagnostic Test Approval | 1 | 2010 | 2 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2014 | 770 | 0.090 |
Why?
|
| General Practitioners | 1 | 2010 | 11 | 0.090 |
Why?
|
| Forecasting | 2 | 2019 | 305 | 0.090 |
Why?
|
| Fractures, Bone | 1 | 2012 | 123 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2014 | 440 | 0.090 |
Why?
|
| Fatty Acids | 1 | 2011 | 131 | 0.090 |
Why?
|
| Quality Control | 1 | 2010 | 116 | 0.090 |
Why?
|
| Physical Exertion | 1 | 2010 | 38 | 0.090 |
Why?
|
| Sample Size | 1 | 2010 | 129 | 0.090 |
Why?
|
| Radiography | 4 | 2014 | 810 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2012 | 233 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 385 | 0.090 |
Why?
|
| Phantoms, Imaging | 1 | 2012 | 450 | 0.090 |
Why?
|
| Prone Position | 1 | 2009 | 56 | 0.080 |
Why?
|
| Reference Values | 1 | 2010 | 665 | 0.080 |
Why?
|
| Canada | 2 | 2022 | 205 | 0.080 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2008 | 50 | 0.080 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2015 | 283 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2010 | 289 | 0.080 |
Why?
|
| Microbubbles | 1 | 2008 | 36 | 0.080 |
Why?
|
| Peptides | 1 | 2012 | 646 | 0.080 |
Why?
|
| Gene Expression | 1 | 2013 | 1308 | 0.080 |
Why?
|
| Observer Variation | 2 | 2014 | 607 | 0.080 |
Why?
|
| Tomography, Spiral Computed | 1 | 2008 | 76 | 0.080 |
Why?
|
| Embolectomy | 1 | 2007 | 6 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2011 | 351 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2009 | 685 | 0.070 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 261 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2016 | 8136 | 0.070 |
Why?
|
| Single-Blind Method | 1 | 2006 | 150 | 0.070 |
Why?
|
| False Positive Reactions | 1 | 2006 | 222 | 0.070 |
Why?
|
| ROC Curve | 1 | 2008 | 773 | 0.070 |
Why?
|
| Intermittent Claudication | 1 | 2005 | 20 | 0.070 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2005 | 9 | 0.070 |
Why?
|
| Esophageal Perforation | 1 | 2005 | 18 | 0.070 |
Why?
|
| Risk | 1 | 2007 | 660 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 525 | 0.070 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2005 | 64 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2008 | 341 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2006 | 235 | 0.060 |
Why?
|
| Aneurysm | 1 | 2005 | 60 | 0.060 |
Why?
|
| Comorbidity | 2 | 2006 | 944 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 224 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2005 | 1542 | 0.060 |
Why?
|
| Probability | 1 | 2006 | 356 | 0.060 |
Why?
|
| Radiation Dosage | 2 | 2016 | 226 | 0.060 |
Why?
|
| Cerebrovascular Disorders | 1 | 2005 | 143 | 0.060 |
Why?
|
| Gallstones | 1 | 2004 | 15 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2005 | 117 | 0.060 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2004 | 7 | 0.060 |
Why?
|
| Extremities | 1 | 2005 | 167 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2005 | 594 | 0.060 |
Why?
|
| Creatine Kinase | 1 | 2004 | 52 | 0.060 |
Why?
|
| Aorta | 1 | 2005 | 286 | 0.060 |
Why?
|
| Myxoma | 1 | 2004 | 30 | 0.060 |
Why?
|
| Myocardial Reperfusion | 1 | 2004 | 28 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 241 | 0.060 |
Why?
|
| Heart Valve Prosthesis | 1 | 2004 | 97 | 0.060 |
Why?
|
| Smoking | 1 | 2007 | 617 | 0.060 |
Why?
|
| Rest | 1 | 2003 | 49 | 0.060 |
Why?
|
| Diabetes Mellitus | 2 | 2007 | 743 | 0.060 |
Why?
|
| Pulmonary Veins | 1 | 2004 | 88 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2005 | 858 | 0.060 |
Why?
|
| Glucuronosyltransferase | 1 | 2004 | 185 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2004 | 272 | 0.060 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 107 | 0.060 |
Why?
|
| Blood Flow Velocity | 1 | 2003 | 199 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1043 | 0.050 |
Why?
|
| California | 1 | 2002 | 143 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2005 | 254 | 0.050 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2005 | 178 | 0.050 |
Why?
|
| Microcirculation | 1 | 2002 | 106 | 0.050 |
Why?
|
| Anemia, Sickle Cell | 1 | 2004 | 143 | 0.050 |
Why?
|
| Allosteric Regulation | 2 | 2013 | 68 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2022 | 79 | 0.050 |
Why?
|
| Length of Stay | 1 | 2005 | 726 | 0.050 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2002 | 99 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 2974 | 0.050 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2002 | 69 | 0.050 |
Why?
|
| Fluorocarbons | 1 | 2002 | 72 | 0.050 |
Why?
|
| Albumins | 1 | 2002 | 130 | 0.050 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2002 | 93 | 0.050 |
Why?
|
| Amino Acid Substitution | 2 | 2013 | 338 | 0.050 |
Why?
|
| Survival Rate | 1 | 2005 | 1881 | 0.050 |
Why?
|
| Arginine Vasopressin | 1 | 2001 | 44 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2004 | 250 | 0.050 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2001 | 39 | 0.050 |
Why?
|
| Neoplasms | 1 | 2016 | 2995 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2004 | 389 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2001 | 80 | 0.050 |
Why?
|
| Mitral Valve Prolapse | 1 | 2000 | 24 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2015 | 1294 | 0.040 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2004 | 516 | 0.040 |
Why?
|
| Adolescent | 3 | 2021 | 9138 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2004 | 1367 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2021 | 268 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2002 | 1847 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2001 | 726 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2015 | 956 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 1093 | 0.040 |
Why?
|
| Animals | 2 | 2013 | 27134 | 0.030 |
Why?
|
| Pregnancy | 1 | 2004 | 2988 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2016 | 121 | 0.030 |
Why?
|
| Drug Inverse Agonism | 1 | 2015 | 3 | 0.030 |
Why?
|
| Scopolamine Derivatives | 1 | 2015 | 4 | 0.030 |
Why?
|
| Tiotropium Bromide | 1 | 2015 | 4 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 85 | 0.030 |
Why?
|
| Radioligand Assay | 1 | 2015 | 32 | 0.030 |
Why?
|
| Muscarinic Agonists | 1 | 2015 | 23 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2015 | 129 | 0.030 |
Why?
|
| Glycosylation | 1 | 2015 | 129 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2015 | 112 | 0.030 |
Why?
|
| Computer Systems | 1 | 2014 | 79 | 0.030 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2013 | 11 | 0.030 |
Why?
|
| Enteroendocrine Cells | 1 | 2013 | 7 | 0.030 |
Why?
|
| Benzeneacetamides | 1 | 2013 | 11 | 0.030 |
Why?
|
| Lipolysis | 1 | 2013 | 23 | 0.030 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2013 | 45 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2013 | 115 | 0.030 |
Why?
|
| Cholesterol | 1 | 2015 | 354 | 0.030 |
Why?
|
| Tibia | 1 | 2013 | 80 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2013 | 100 | 0.030 |
Why?
|
| Orexin Receptors | 1 | 2012 | 1 | 0.030 |
Why?
|
| Orexins | 1 | 2012 | 8 | 0.030 |
Why?
|
| Fourier Analysis | 1 | 2012 | 126 | 0.030 |
Why?
|
| Larynx | 1 | 2012 | 38 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 71 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 77 | 0.030 |
Why?
|
| Adipocytes | 1 | 2013 | 163 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 423 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 2499 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 2332 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2013 | 328 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 510 | 0.020 |
Why?
|
| Biosensing Techniques | 1 | 2012 | 73 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 740 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 767 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2012 | 331 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2012 | 276 | 0.020 |
Why?
|
| Systole | 1 | 2010 | 114 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 1112 | 0.020 |
Why?
|
| Awareness | 1 | 2010 | 89 | 0.020 |
Why?
|
| Child | 2 | 2015 | 7082 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 454 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1128 | 0.020 |
Why?
|
| Kinetics | 1 | 2012 | 1529 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1482 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 6179 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 244 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2012 | 1095 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2008 | 144 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 355 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 4030 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2873 | 0.020 |
Why?
|
| Body Surface Area | 1 | 2005 | 36 | 0.020 |
Why?
|
| Midwestern United States | 1 | 2005 | 82 | 0.020 |
Why?
|
| Shock | 1 | 2005 | 44 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 307 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2402 | 0.020 |
Why?
|
| Heart Valve Diseases | 1 | 2005 | 115 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 2004 | 114 | 0.010 |
Why?
|
| Age of Onset | 1 | 2004 | 311 | 0.010 |
Why?
|
| Equipment Design | 1 | 2005 | 415 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 544 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 2005 | 232 | 0.010 |
Why?
|
| Educational Measurement | 1 | 2005 | 230 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2005 | 381 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 901 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 2004 | 203 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2004 | 423 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 2333 | 0.010 |
Why?
|
| Aging | 1 | 2004 | 708 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 1867 | 0.010 |
Why?
|
| Students, Medical | 1 | 2005 | 418 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 11685 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 1308 | 0.010 |
Why?
|